Buy Selank in India: Anxiolytic Peptide Research Guide

Selank is a synthetic heptapeptide derived from the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tripeptide to improve metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences — the same institution behind Semax — Selank was designed to deliver the anxiolytic effects of benzodiazepines without their sedative, amnestic, or dependency-forming properties. It has been used clinically in Russia for generalised anxiety disorder and is registered as a pharmaceutical there.

What Is Selank?

Tuftsin, Selank's parent molecule, is a natural fragment of the heavy chain of immunoglobulin G. It is produced endogenously in the spleen and has known immunomodulatory and anxiolytic properties. By appending the PGP stabilising sequence, researchers created a peptide that survives nasal mucosal enzymes long enough to cross into the CNS via the olfactory route — the same pathway used by Semax. Selank's mechanism of action is multifactorial: it modulates GABA-A receptor sensitivity, increases enkephalin expression, and normalises serotonin turnover in the amygdala and hippocampus — the brain's primary anxiety-processing centres.

Key Research Applications

Anxiety and GABA Modulation

Selank's primary and best-characterised effect is anxiolysis without sedation. Unlike benzodiazepines, which are positive allosteric modulators of the GABA-A receptor producing broad CNS depression, Selank appears to act more selectively — normalising GABAergic tone in limbic structures without the general inhibitory effect on alertness and motor coordination. In animal models of anxiety, Selank consistently reduces anxiety-related behaviours in elevated plus-maze and open-field tests at doses that leave locomotion unimpaired — a critical distinction that benzodiazepines cannot achieve at anxiolytic doses.

Cortisol Reduction and Stress Response

One of the most clinically relevant findings in Selank research is its effect on the hypothalamic-pituitary-adrenal (HPA) axis. Repeated Selank administration normalises elevated cortisol in stressed subjects without suppressing the normal stress response entirely. This HPA normalisation is distinct from cortisol blockers or synthetic glucocorticoid suppressants — Selank appears to recalibrate set-points rather than block the axis. For researchers studying chronic stress models, this nuanced regulation is a significant advantage over blunter pharmacological interventions.

Mood Improvement Without Sedation

Clinical studies in Russia — including double-blind placebo-controlled trials in anxiety disorder patients — reported significant improvements in mood, irritability, and subjective sense of well-being without the cognitive blunting typical of sedative anxiolytics. Subjects remained alert and cognitively functional while experiencing reduced anxiety. This profile makes Selank uniquely valuable for research into conditions where anxiety co-exists with the need for cognitive performance — a combination that traditional anxiolytics handle poorly.

Enkephalin Stabilisation

Selank inhibits the enzymes responsible for degrading met-enkephalin and leu-enkephalin, the endogenous opioid pentapeptides that modulate mood, pain perception, and immune function. By prolonging enkephalin activity at opioid receptors, Selank contributes to mood elevation and stress resilience via a mechanism entirely separate from its GABAergic actions. This dual-pathway anxiolysis — GABAergic calming plus opioidergic mood support — is mechanistically richer than single-target anxiolytics.

Immune Modulation

As a tuftsin derivative, Selank retains immunomodulatory properties. Research has shown it can upregulate interferon expression and modulate T-cell and NK-cell activity. While this is secondary to its primary neurological applications, researchers studying the brain-immune axis and psychoneuroimmunology have found Selank an interesting tool given its simultaneous activity across both systems.

Dosage Protocol

Standard research dosage: 250–500 mcg per day intranasally, typically split into 2–3 doses of 125–250 mcg each

Cycle length: 2–4 weeks on with equal time off; some protocols run 10-day courses

Administration: Intranasal drops or spray; onset is typically 15–30 minutes via the olfactory route. For subcutaneous administration, use the BAC water calculator to calculate reconstitution volumes accurately.

Storage

Selank solution is sensitive to light and heat. Store refrigerated at 2–8°C and protect from direct light. Lyophilised powder should be kept at -20°C until reconstitution. Once reconstituted, use within 3–4 weeks; avoid repeated freeze-thaw cycles by preparing small working aliquots.

Selank and Semax: A Balanced Nootropic Stack

Selank and Semax are frequently studied together as a complementary cognitive stack. Semax provides the stimulatory, BDNF-upregulating, pro-cognitive component; Selank provides the anxiolytic stabilisation that prevents the cortisol elevation and mental fatigue that can arise with stimulatory nootropics. The two peptides use different primary mechanisms — Semax via melanocortin and BDNF pathways, Selank via GABA and enkephalin — meaning they do not compete and can be dosed simultaneously or at different times of day depending on the research protocol.

Where to Buy Selank in India

Peptide Central stocks Selank at 99% purity, independently HPLC-verified with Certificate of Analysis included. Pan-India COD delivery available. Contact us via WhatsApp for current pricing, formulation options, and stock confirmation.